Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024
HONG KONG,Sept. 16,2024-- At the 2024 European Society for Medical Oncology (ESMO) Conference,Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a f